Changes in gene expression during progression of ovarian carcinoma

The molecular events leading to the development and progression of serous ovarian carcinoma are not completely understood. We performed a large scale survey for the identification of differentially expressed genes in serous ovarian carcinoma by using cDNA array analysis. Differences in gene expression between serous adenocarcinoma and benign serous adenoma, and between advanced and/or moderately or poorly differentiated and local, highly differentiated serous adenocarcinoma were assessed. The most striking difference between adenocarcinoma and benign adenoma was upregulation of RHOGDI2 in the carcinomas irrespective of the clinical tumor stage. Other changes in carcinoma were upregulation of MET and Ne-dlg, and downregulation of HGFAC, desmin, and PDGFA. The most prominent differences between advanced and local adenocarcinoma were upregulation of COL3A1, CFGR, and MET in advanced carcinoma, and downregulation of HGFAC, FZD3, and BFL1 in the same tumors. In conclusion, significant differences were found in the gene expression between benign and malignant serous ovarian tumors, and between local, highly differentiated and advanced and/or moderately or poorly differentiated serous adenocarcinomas. The differentially expressed genes may be related to the carcinogenesis and progression of the malignant growth.

[1]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[2]  D. Pinkel,et al.  Genetic analysis of benign, low-grade, and high-grade ovarian tumors. , 1995, Cancer research.

[3]  U. Puistola,et al.  Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. , 1993, Cancer research.

[4]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[5]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[6]  K. Miyazawa,et al.  Activation of Hepatocyte Growth Factor in the Injured Tissues Is Mediated by Hepatocyte Growth Factor Activator (*) , 1996, The Journal of Biological Chemistry.

[7]  R. Lin,et al.  Specific Contributions of the Small GTPases Rho, Rac, and Cdc42 to Dbl Transformation* , 1999, The Journal of Biological Chemistry.

[8]  S. Knuutila,et al.  Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. , 1997, British Journal of Cancer.

[9]  S. Jimenez,et al.  Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. , 1997, The international journal of biochemistry & cell biology.

[10]  F. Mitelman,et al.  Chromosome aberrations in 35 primary ovarian carcinomas , 1992, Genes, chromosomes & cancer.

[11]  J. Risteli,et al.  Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. , 1996, The American journal of pathology.

[12]  B. Olofsson,et al.  Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. , 1999, Cellular signalling.

[13]  H. Nevanlinna,et al.  Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32. , 1998, Cancer research.

[14]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[15]  P Zola,et al.  Overexpression of the MET/HGF receptor in ovarian cancer , 1994, International journal of cancer.

[16]  J. Risteli,et al.  Aberrant type I and type III collagen gene expression in human breast cancer in vivo , 1998, The Journal of pathology.

[17]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[18]  D. Danley,et al.  Defective Rho GTPase regulation by IL-1 beta-converting enzyme-mediated cleavage of D4 GDP dissociation inhibitor. , 1996, Journal of immunology.

[19]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[20]  Channing J Der,et al.  Rho family proteins and Ras transformation: the RHOad less traveled gets congested , 1998, Oncogene.

[21]  H. Tsubouchi,et al.  Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c‐met genes in human glioma cells in vitro , 1995, FEBS letters.

[22]  K. Aihara,et al.  Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. , 1997, American journal of clinical pathology.

[23]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.